...
首页> 外文期刊>Molecular pharmaceutics >Multifunctional Poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin Amphiphilic Copolymer as an Oral High-Performance Delivery Carrier of Tacrolimus
【24h】

Multifunctional Poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin Amphiphilic Copolymer as an Oral High-Performance Delivery Carrier of Tacrolimus

机译:多功能聚甲基乙烯基醚-顺丁烯二酸酐-接枝羟丙基-β-环糊精两亲共聚物为他克莫司的口服高性能传递载体

获取原文
获取原文并翻译 | 示例
           

摘要

In order to improve oral bioavailability of tacrolimus (FK506), a novel poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cydodextrin amphiphilic copolymer (CD-PVM/MA) is developed, combining the bioadhesiveness of PVM/MA, P-glycoprotein (P-gp), and cytochrome P450-inhibitory effect of CD into one. The FK506-loaded nanoparticles (CD-PVM/MA-NPs) were obtained by solvent evaporation method. The physiochemical properties and intestinal absorption mechanism of FK506-loaded CD-PVM/MA-NPs were characterized, and the pharmacokinetic behavior was investigated in rats. FK506-loaded CD-PVM/MA-NPs exhibited nanometer-sized particles of 273.7 nm, with encapsulation efficiency as high as 73.3%. FK506-loaded CD-PVM/MA-NPs maintained structural stability in the simulated gastric fluid, and about 80% FK506 was released within 24 h in the simulated intestinal fluid. The permeability of FK506 was improved dramatically by CD-PVM/MA-NPs compared to its solution, probably due to the synergistic inhibition effect of P-gp and cytochrome P450 3A (CYP3A). The intestinal biodistribution of fluorescence-labeled CD-PVM/MA-NPs confirmed its good bioadhesion to the rat intestinal wall. Two endocytosis pathways, clathrin- and caveolae-mediated endocytosis, were involved in the cellular uptake of CD-PVM/MA-NPs. The important role of lymphatic transport in nanoparticles access to the systemic circulation, about half of the contribution to oral bioavailability, was observed in mesenteric lymph duct ligated rats. The AUC(0-24) of FK506 loaded in nanoparticles was enhanced up to 20-fold compared to FK506 solutions after oral administration. The present study suggested that the novel multifunctional CD-PVM/MA is a promising efficient oral delivery carrier for FK506, due to its ability in solubilization, inhibitory effects on both P-gp and CYP 3A, high bioadhesion, and sustained release capability.
机译:为了提高他克莫司(FK506)的口服生物利用度,结合了PVM的生物粘附性,开发了一种新型的聚(甲基乙烯基醚-马来酸酐)-接枝羟丙基-β-环糊精两亲共聚物(CD-PVM / MA)。 / MA,P-糖蛋白(P-gp)和细胞色素P450抑制CD的作用合二为一。通过溶剂蒸发法获得了载有FK506的纳米颗粒(CD-PVM / MA-NPs)。表征了FK506加载CD-PVM / MA-NPs的理化性质和肠道吸收机制,并研究了大鼠的药代动力学行为。装载FK506的CD-PVM / MA-NPs表现出273.7 nm的纳米尺寸颗粒,封装效率高达73.3%。载有FK506的CD-PVM / MA-NPs在模拟胃液中保持结构稳定性,并且在模拟肠液中24小时内释放了约80%的FK506。与它的溶液相比,CD-PVM / MA-NPs大大提高了FK506的通透性,这可能是由于P-gp和细胞色素P450 3A(CYP3A)的协同抑制作用。荧光标记的CD-PVM / MA-NPs的肠道生物分布证实了其对大鼠肠壁的良好生物粘附性。两种内吞途径,网格蛋白和小窝介导的内吞作用,参与了CD-PVM / MA-NPs的细胞摄取。在结扎肠系膜淋巴管的大鼠中观察到淋巴运输在纳米颗粒进入体循环中的重要作用,约占口服生物利用度的一半。与口服给药后的FK506溶液相比,纳米颗粒中FK506的AUC(0-24)增强了20倍。本研究表明,新型多功能CD-PVM / MA由于具有增溶能力,对P-gp和CYP 3A的抑制作用,高生物粘附性和持续释放能力,因此是FK506的有希望的有效口服递送载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号